Please assess the completion status of the following clinical trial:

Trial Title: GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hemodialysis patient with a dysfunctional or thrombosed forearm or upper arm prosthetic vascular access graft.~* The target lesion starts less than or equal to 30 mm from the venous anastomosis.~* The target lesion has \> 50% stenosis as measured per protocol.~* The patient has a maximum of one secondary stenosis.~Exclusion Criteria:~* The age of the hemodialysis access graft is less than or equal to 30 days old from the date of the study procedure.~* The patient has undergone an intervention (surgical or percutaneous) of the vascular access circuit less than or equal to 30 days from the date of the study procedure.~* The secondary lesion is an occlusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VIABAHN Treatment Group (Type: EXPERIMENTAL): Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm
- PTA Treatment Group (Type: ACTIVE_COMPARATOR): Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).